Dr. Staph Leavenworth Bakali

Dr. Mustapha (“Staph”) Leavenworth Bakali holds a First Class Honours Degree from City of London Polytechnic and an MSc (With Distinction) from London Business School. He is President and Chief Operating Officer of the Clinton Health Access Initiative (CHAI).
Dr. Staph Leavenworth Bakali has 24 years of global business experience in building and managing large and early stage operations in the Life Sciences sector. He served 11 years with SmithKline Beecham in many leadership roles worldwide. Previously, he was Chief Business Officer of Intercell AG as well as President of Genocea Biosciences.
As Chief Operation Officer of ID Biomedical and PowderJect Pharmaceuticals Plc, he played a significant role in transforming the two companies into fully-integrated biotech companies leading to acquisitions by GlaxoSmithKline and Chiron Corporation. 
As Worldwide Head of Sales and Marketing of Chiron Corporation’s Vaccines Division, his negotiations resulted in the development of a low-cost combination pentavalent vaccine to serve children across the world’s poorest countries. 
Dr. Staph Leavenworth Bakali co-founded LeapFrog Investments, the world’s first and largest investor in companies that insure underserved people in Africa and Asia. He serves on numerous boards as an advisor and as a non-Executive Director.

Prof. Dr. Erich Schlick

Dr. Erich Schlick studied medicine in Berlin, Mainz and Heidelberg. He specialized in oncology and immunology at the US National Cancer Institute. Dr. Erich Schlick holds a professorship of immune pharmacology at the University of Heidelberg.
In the 1990s, Dr. Erich Schlick initiated the development of Humira, the first fully human therapeutic monoclonal antibody. His innovation became a Blockbuster. Before working in venture capital, Dr. Erich Schlick spent 15 years with BASF Pharma / Knoll AG, 10 ten years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira for the treatment of rheumatoid arthritis and other autoimmune diseases. 
Dr. Erich Schlick served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head of 3i Healthcare Worldwide. In 2005, Dr. Erich Schlick joined Wellington as an Investment Partner for Life Sciences and has since then been responsible for many successful European biotech and medtech companies.

Dr. Markus Hosang

Dr. Markus Hosang received his M.S. and Ph.D. degrees in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School and the University of Washington in Seattle. In 2005 Dr. Hosang joined BioMedPartners as a General Partner. Since then he has been on the boards of many European biotech and medtech companies, some of which have been sold or gone public very successfully.
Dr. Markus Hosang has a strong pharmaceutical background and is very experienced in VC. Previously, he served as Venture Partner at MPM Capital, where he was co-responsible for the European deal flow and managed the European office in Munich.
Before joining MPM in 2002, he was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. 
Dr. Markus Hosang served on the Global Board of R&D Directors and the Pharma Portfolio Board. Subsequently he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee.

Dr. Stefan Herr

Dr. Stefan Herr earned his Ph.D. in Physics from the University of Heidelberg and received additional training in law and business at the University of Hagen. He was a recipient of the Boehringer Ingelheim Fellowship and is an alumnus of the European Molecular Biology Laboratory Ph.D. program.
In 2001, Dr. Stefan Herr started EMBL Ventures. He led several investments in Europe and the US for EMBL Ventures, Heidelberg Innovation and as Business Angel. 
Before joining EMBL Ventures, he served as Managing Director of Verivox, a 3i backed start-up company. Previously Dr. Stefan Herr was Vice President at Heidelberg Innovation and Director Cooperations and Licensing at Hagenuk.

Dr. Ulrich Granzer

Ulrich Granzer, Ph.D., the founder of Granzer Regulatory Consulting & Services, graduated as a pharmacist in 1984 from the University of Marburg, followed by Ph.D. studies during which he also acted as a lecturer for pharmaceutical chemistry. In 1988 he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety.
In 1989, Dr. Ulrich Granzer started his industry career in the Regulatory Affairs department at Glaxo. In 1993 he was appointed Director of Regulatory Affairs. After that, he served as a member of Glaxo Wellcome's Global Regulatory Board. In 1998, Dr. Ulrich Granzer joined BASF Pharma as Vice President of Global Regulatory Centres, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development.
At Knoll, he was responsible for the development of small molecules as well as several biological compounds in the indications of stroke, septic shock, and rheumatoid arthritis. He was instrumental in the program for the first fully human anti-TNF antibody, now marketed as Humira. After Knoll had been taken over by Abbott, Dr. Ulrich Granzer joined Bayer as Vice President Global Regulatory Affairs with the responsibility for all regulatory aspects of development and submission projects worldwide.
In 2002 Dr. Ulrich Granzer founded Granzer Regulatory Consulting & Services. The company has steadily grown since and today employs 25 highly experienced consultants.